Global Covid-19 vaccines equity of access is a 'shared goal' as production surges, says industry

16 May 2022

Global equity of access to Covid-19 vaccines should be a shared goal, according to the research-based biopharmaceutical industry, with production set to reach 16.3 billion doses by the end of June.

In a joint statement at the Oireachtas Committee on Enterprise, Trade and Employment, IPHA and BPCI, the industry’s representative organizations, said waiving intellectual property rights will not accelerate global Covid-19 vaccines access.

“Production is not the problem. There are already more than enough vaccines for the world. The problem is they are not getting to the people who most need them fast enough,” said Oliver O’Connor, chief executive of the Irish Pharmaceutical Healthcare Association (IPHA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK